APO Research
Talk to an analyst

APO RESEARCH · REPORT

Myasthenia Gravis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Myasthenia Gravis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchMyasthenia Gravis Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Myasthenia Gravis Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Myasthenia Gravis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myasthenia Gravis Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Myasthenia Gravis Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Myasthenia Gravis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Myasthenia Gravis Drugs include Alexion Pharmaceuticals, Bausch Health, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, F. Hoffmann-La Roche, Flamel Technologies and Galencia, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Myasthenia Gravis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Myasthenia Gravis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Myasthenia Gravis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Myasthenia Gravis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Myasthenia Gravis Drugs Segment by Company

Alexion Pharmaceuticals

Bausch Health

Catalyst Pharmaceuticals

CSL

Curavac

Cytokinetics

F. Hoffmann-La Roche

Flamel Technologies

Galencia

GlaxoSmithKline

Grifols

Lupin Pharmaceuticals

Mitsubishi Tanabe Pharma

Pfizer

Novartis

Takeda

Myasthenia Gravis Drugs Segment by Type

Intravenous Immune Globulins

Anticholinesterases

Immunosuppressants

Myasthenia Gravis Drugs Segment by Application

Hospitals

Clinics

Myasthenia Gravis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myasthenia Gravis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myasthenia Gravis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myasthenia Gravis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Myasthenia Gravis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Myasthenia Gravis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Myasthenia Gravis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Myasthenia Gravis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Myasthenia Gravis Drugs Industry Trends Table 2. Myasthenia Gravis Drugs Industry Drivers Table 3. Myasthenia Gravis Drugs Industry Opportunities and Challenges Table 4. Myasthenia Gravis Drugs Industry Restraints Table 5. Global Myasthenia Gravis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Myasthenia Gravis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Myasthenia Gravis Drugs Sales by Manufacturers (Tons) & (2021-2026) Table 8. Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers Table 9. Global Myasthenia Gravis Drugs Average Sales Price (US$/Kg) of Manufacturers (2021-2026) Table 10. Global Myasthenia Gravis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Myasthenia Gravis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Myasthenia Gravis Drugs Manufacturers, Product Type & Application Table 13. Global Myasthenia Gravis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Myasthenia Gravis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Intravenous Immune Globulins Table 17. Major Manufacturers of Anticholinesterases Table 18. Major Manufacturers of Immunosuppressants Table 19. Global Myasthenia Gravis Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Myasthenia Gravis Drugs Sales by Type (2021-2026) & (Tons) Table 21. Global Myasthenia Gravis Drugs Sales by Type (2027-2032) & (Tons) Table 22. Global Myasthenia Gravis Drugs Sales Market Share by Type (2021-2026) Table 23. Global Myasthenia Gravis Drugs Sales Market Share by Type (2027-2032) Table 24. Global Myasthenia Gravis Drugs Revenue by Type 2021 VS 2025 VS 2032 (Tons) Table 25. Global Myasthenia Gravis Drugs Revenue by Type (2021-2026) & (Tons) Table 26. Global Myasthenia Gravis Drugs Revenue by Type (2027-2032) & (Tons) Table 27. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Global Myasthenia Gravis Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 32. Global Myasthenia Gravis Drugs Sales by Application (2021-2026) & (Tons) Table 33. Global Myasthenia Gravis Drugs Sales by Application (2027-2032) & (Tons) Table 34. Global Myasthenia Gravis Drugs Sales Market Share by Application (2021-2026) Table 35. Global Myasthenia Gravis Drugs Sales Market Share by Application (2027-2032) Table 36. Global Myasthenia Gravis Drugs Revenue by Application 2021 VS 2025 VS 2032 (Tons) Table 37. Global Myasthenia Gravis Drugs Revenue by Application (2021-2026) & (Tons) Table 38. Global Myasthenia Gravis Drugs Revenue by Application (2027-2032) & (Tons) Table 39. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 42. Global Myasthenia Gravis Drugs Sales by Region (2021-2026) & (Tons) Table 43. Global Myasthenia Gravis Drugs Sales Market Share by Region (2021-2026) Table 44. Global Myasthenia Gravis Drugs Sales Forecasted by Region (2027-2032) & (Tons) Table 45. Global Myasthenia Gravis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 47. North America Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 48. North America Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 49. Europe Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 50. Europe Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 51. Europe Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 52. Asia Pacific Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 53. Asia Pacific Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 54. Asia Pacific Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 55. South America, Middle East and Africa Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. South America, Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 57. South America, Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 58. Global Myasthenia Gravis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Myasthenia Gravis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Myasthenia Gravis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2027-2032) Table 63. Alexion Pharmaceuticals Company Information Table 64. Alexion Pharmaceuticals Business Overview Table 65. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 67. Alexion Pharmaceuticals Recent Development Table 68. Bausch Health Company Information Table 69. Bausch Health Business Overview Table 70. Bausch Health Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bausch Health Myasthenia Gravis Drugs Product Portfolio Table 72. Bausch Health Recent Development Table 73. Catalyst Pharmaceuticals Company Information Table 74. Catalyst Pharmaceuticals Business Overview Table 75. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 77. Catalyst Pharmaceuticals Recent Development Table 78. CSL Company Information Table 79. CSL Business Overview Table 80. CSL Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. CSL Myasthenia Gravis Drugs Product Portfolio Table 82. CSL Recent Development Table 83. Curavac Company Information Table 84. Curavac Business Overview Table 85. Curavac Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Curavac Myasthenia Gravis Drugs Product Portfolio Table 87. Curavac Recent Development Table 88. Cytokinetics Company Information Table 89. Cytokinetics Business Overview Table 90. Cytokinetics Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cytokinetics Myasthenia Gravis Drugs Product Portfolio Table 92. Cytokinetics Recent Development Table 93. F. Hoffmann-La Roche Company Information Table 94. F. Hoffmann-La Roche Business Overview Table 95. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio Table 97. F. Hoffmann-La Roche Recent Development Table 98. Flamel Technologies Company Information Table 99. Flamel Technologies Business Overview Table 100. Flamel Technologies Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Flamel Technologies Myasthenia Gravis Drugs Product Portfolio Table 102. Flamel Technologies Recent Development Table 103. Galencia Company Information Table 104. Galencia Business Overview Table 105. Galencia Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Galencia Myasthenia Gravis Drugs Product Portfolio Table 107. Galencia Recent Development Table 108. GlaxoSmithKline Company Information Table 109. GlaxoSmithKline Business Overview Table 110. GlaxoSmithKline Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio Table 112. GlaxoSmithKline Recent Development Table 113. Grifols Company Information Table 114. Grifols Business Overview Table 115. Grifols Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Grifols Myasthenia Gravis Drugs Product Portfolio Table 117. Grifols Recent Development Table 118. Lupin Pharmaceuticals Company Information Table 119. Lupin Pharmaceuticals Business Overview Table 120. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 122. Lupin Pharmaceuticals Recent Development Table 123. Mitsubishi Tanabe Pharma Company Information Table 124. Mitsubishi Tanabe Pharma Business Overview Table 125. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio Table 127. Mitsubishi Tanabe Pharma Recent Development Table 128. Pfizer Company Information Table 129. Pfizer Business Overview Table 130. Pfizer Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Pfizer Myasthenia Gravis Drugs Product Portfolio Table 132. Pfizer Recent Development Table 133. Novartis Company Information Table 134. Novartis Business Overview Table 135. Novartis Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Novartis Myasthenia Gravis Drugs Product Portfolio Table 137. Novartis Recent Development Table 138. Takeda Company Information Table 139. Takeda Business Overview Table 140. Takeda Myasthenia Gravis Drugs Sales (Tons), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Takeda Myasthenia Gravis Drugs Product Portfolio Table 142. Takeda Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Myasthenia Gravis Drugs Distributors List Table 146. Myasthenia Gravis Drugs Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Myasthenia Gravis Drugs Product Image Figure 2. Global Myasthenia Gravis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Myasthenia Gravis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Myasthenia Gravis Drugs Sales (2021-2032) & (Tons) Figure 5. Global Myasthenia Gravis Drugs Average Price (US$/Kg) & (2021-2032) Figure 6. Global Top 5 and 10 Myasthenia Gravis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Intravenous Immune Globulins Image Figure 9. Anticholinesterases Image Figure 10. Immunosuppressants Image Figure 11. Global Myasthenia Gravis Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Myasthenia Gravis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Myasthenia Gravis Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Myasthenia Gravis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Tons) Figure 15. Global Myasthenia Gravis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Global Myasthenia Gravis Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 20. Global Myasthenia Gravis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Myasthenia Gravis Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Myasthenia Gravis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Tons) Figure 23. Global Myasthenia Gravis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 26. North America Myasthenia Gravis Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 28. Canada Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 29. Mexico Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 30. Europe Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 31. Europe Myasthenia Gravis Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 33. France Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 34. U.K. Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 35. Italy Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 36. Netherlands Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 37. Asia Pacific Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 38. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Country (2021-2032) Figure 39. China Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 40. Japan Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 41. South Korea Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 42. Southeast Asia Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 43. India Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 44. Australia Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 45. South America, Middle East and Africa Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 46. South America, Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 48. South Africa Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 49. Saudi Arabia Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 50. Turkey Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 51. Argentina Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 52. UAE Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 53. Egypt Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 54. Chile Myasthenia Gravis Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 55. Global Myasthenia Gravis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Myasthenia Gravis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Myasthenia Gravis Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Myasthenia Gravis Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Myasthenia Gravis Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous Immune Globulins
  • Anticholinesterases
  • Immunosuppressants
Applications
  • Hospitals
  • Clinics
Companies covered
  • Alexion Pharmaceuticals
  • Bausch Health
  • Catalyst Pharmaceuticals
  • CSL
  • Curavac
  • Cytokinetics
  • F. Hoffmann-La Roche
  • Flamel Technologies
  • Galencia
  • GlaxoSmithKline
  • Grifols
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Pfizer
  • Novartis
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Myasthenia Gravis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Myasthenia Gravis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Myasthenia Gravis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Myasthenia Gravis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Myasthenia Gravis Drugs Market Dynamics
  1. 2.1 Myasthenia Gravis Drugs Industry Trends
  2. 2.2 Myasthenia Gravis Drugs Industry Drivers
  3. 2.3 Myasthenia Gravis Drugs Industry Opportunities and Challenges
  4. 2.4 Myasthenia Gravis Drugs Industry Restraints
3 Myasthenia Gravis Drugs Market by Manufacturers
  1. 3.1 Global Myasthenia Gravis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Myasthenia Gravis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Myasthenia Gravis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Myasthenia Gravis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Myasthenia Gravis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Myasthenia Gravis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Myasthenia Gravis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Myasthenia Gravis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Myasthenia Gravis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Myasthenia Gravis Drugs Tier 1, Tier 2, and Tier 3
4 Myasthenia Gravis Drugs Market by Type
  1. 4.1 Myasthenia Gravis Drugs Type Introduction
  2. 4.1.1 Intravenous Immune Globulins
  3. 4.1.2 Anticholinesterases
  4. 4.1.3 Immunosuppressants
  5. 4.2 Global Myasthenia Gravis Drugs Sales by Type
  6. 4.2.1 Global Myasthenia Gravis Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Myasthenia Gravis Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Myasthenia Gravis Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Myasthenia Gravis Drugs Revenue by Type
  10. 4.3.1 Global Myasthenia Gravis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Myasthenia Gravis Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2021-2032)
5 Myasthenia Gravis Drugs Market by Application
  1. 5.1 Myasthenia Gravis Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.2 Global Myasthenia Gravis Drugs Sales by Application
  5. 5.2.1 Global Myasthenia Gravis Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Myasthenia Gravis Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Myasthenia Gravis Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Myasthenia Gravis Drugs Revenue by Application
  9. 5.3.1 Global Myasthenia Gravis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Myasthenia Gravis Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Myasthenia Gravis Drugs Revenue Market Share by Application (2021-2032)
6 Global Myasthenia Gravis Drugs Sales by Region
  1. 6.1 Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Myasthenia Gravis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Myasthenia Gravis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Myasthenia Gravis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Myasthenia Gravis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Myasthenia Gravis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Myasthenia Gravis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Myasthenia Gravis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Myasthenia Gravis Drugs Revenue by Region
  1. 7.1 Global Myasthenia Gravis Drugs Revenue by Region
  2. 7.1.1 Global Myasthenia Gravis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Myasthenia Gravis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Myasthenia Gravis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Myasthenia Gravis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Myasthenia Gravis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Myasthenia Gravis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Myasthenia Gravis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Myasthenia Gravis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Myasthenia Gravis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals
  2. 8.1.1 Alexion Pharmaceuticals Company Information
  3. 8.1.2 Alexion Pharmaceuticals Business Overview
  4. 8.1.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals Recent Developments
  7. 8.2 Bausch Health
  8. 8.2.1 Bausch Health Company Information
  9. 8.2.2 Bausch Health Business Overview
  10. 8.2.3 Bausch Health Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bausch Health Myasthenia Gravis Drugs Product Portfolio
  12. 8.2.5 Bausch Health Recent Developments
  13. 8.3 Catalyst Pharmaceuticals
  14. 8.3.1 Catalyst Pharmaceuticals Company Information
  15. 8.3.2 Catalyst Pharmaceuticals Business Overview
  16. 8.3.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  18. 8.3.5 Catalyst Pharmaceuticals Recent Developments
  19. 8.4 CSL
  20. 8.4.1 CSL Company Information
  21. 8.4.2 CSL Business Overview
  22. 8.4.3 CSL Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CSL Myasthenia Gravis Drugs Product Portfolio
  24. 8.4.5 CSL Recent Developments
  25. 8.5 Curavac
  26. 8.5.1 Curavac Company Information
  27. 8.5.2 Curavac Business Overview
  28. 8.5.3 Curavac Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Curavac Myasthenia Gravis Drugs Product Portfolio
  30. 8.5.5 Curavac Recent Developments
  31. 8.6 Cytokinetics
  32. 8.6.1 Cytokinetics Company Information
  33. 8.6.2 Cytokinetics Business Overview
  34. 8.6.3 Cytokinetics Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cytokinetics Myasthenia Gravis Drugs Product Portfolio
  36. 8.6.5 Cytokinetics Recent Developments
  37. 8.7 F. Hoffmann-La Roche
  38. 8.7.1 F. Hoffmann-La Roche Company Information
  39. 8.7.2 F. Hoffmann-La Roche Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Recent Developments
  43. 8.8 Flamel Technologies
  44. 8.8.1 Flamel Technologies Company Information
  45. 8.8.2 Flamel Technologies Business Overview
  46. 8.8.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Flamel Technologies Myasthenia Gravis Drugs Product Portfolio
  48. 8.8.5 Flamel Technologies Recent Developments
  49. 8.9 Galencia
  50. 8.9.1 Galencia Company Information
  51. 8.9.2 Galencia Business Overview
  52. 8.9.3 Galencia Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Galencia Myasthenia Gravis Drugs Product Portfolio
  54. 8.9.5 Galencia Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Grifols
  62. 8.11.1 Grifols Company Information
  63. 8.11.2 Grifols Business Overview
  64. 8.11.3 Grifols Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Grifols Myasthenia Gravis Drugs Product Portfolio
  66. 8.11.5 Grifols Recent Developments
  67. 8.12 Lupin Pharmaceuticals
  68. 8.12.1 Lupin Pharmaceuticals Company Information
  69. 8.12.2 Lupin Pharmaceuticals Business Overview
  70. 8.12.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  72. 8.12.5 Lupin Pharmaceuticals Recent Developments
  73. 8.13 Mitsubishi Tanabe Pharma
  74. 8.13.1 Mitsubishi Tanabe Pharma Company Information
  75. 8.13.2 Mitsubishi Tanabe Pharma Business Overview
  76. 8.13.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio
  78. 8.13.5 Mitsubishi Tanabe Pharma Recent Developments
  79. 8.14 Pfizer
  80. 8.14.1 Pfizer Company Information
  81. 8.14.2 Pfizer Business Overview
  82. 8.14.3 Pfizer Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Pfizer Myasthenia Gravis Drugs Product Portfolio
  84. 8.14.5 Pfizer Recent Developments
  85. 8.15 Novartis
  86. 8.15.1 Novartis Company Information
  87. 8.15.2 Novartis Business Overview
  88. 8.15.3 Novartis Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Novartis Myasthenia Gravis Drugs Product Portfolio
  90. 8.15.5 Novartis Recent Developments
  91. 8.16 Takeda
  92. 8.16.1 Takeda Company Information
  93. 8.16.2 Takeda Business Overview
  94. 8.16.3 Takeda Myasthenia Gravis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Takeda Myasthenia Gravis Drugs Product Portfolio
  96. 8.16.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Myasthenia Gravis Drugs Value Chain Analysis
  2. 9.1.1 Myasthenia Gravis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Myasthenia Gravis Drugs Production Mode & Process
  6. 9.2 Myasthenia Gravis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Myasthenia Gravis Drugs Distributors
  9. 9.2.3 Myasthenia Gravis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst